Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

PMSI Settlement SolutionsSM Appeals To CMS On Drug Review Methods In Medicare Set-Asides
PMSI Settlement Solutions, a leading solutions provider for liability and workers" compensation claims, announced its initiative to address payor concerns regarding the Centers for Medicare and Medicaid Services (CMS) new prescription drug requirement associated with Medicare Set-Asides (MSA"s). As part of this initiative, PMSI Settlement Solutions will work with government affairs experts, industry consultants and other interested payors.

Massachusetts Officials Issue Directive That Seeks To Streamline HIV Testing Consent Process
The Massachusetts Department of Public Health yesterday issued a directive recommending that health care providers include written consent for HIV testing in the general permission forms given to patients receiving medical care, the Boston Globe reports. State health care providers typically give patients separate consent forms for HIV testing, a practice health officials say poses as a barrier to HIV testing for patients and their providers. The new Massachusetts recommendation states that HIV testing should be explicitly mentioned on standard general consent forms. Reinforcing a provision in the CDC"s 2006 HIV testing guidelines, the directive also recommends routine HIV testing for all residents age 13 to 64 in health care settings. Patients in Massachusetts must still opt in to HIV testing, whereas the CDC recommends that HIV testing be performed unless a patient opts out, according to the Globe (Cooney, Boston Globe, 6/25).
News of the day
Norway Chooses The Four-Type HPV Vaccine Gardasil(R) For The National Vaccination Programme
The four-type (6,11,16,18) human papillomavirus (HPV) vaccine, Gardasil®, has been chosen by the Norwegian authorities for the national vaccination programme after the assessment of a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection. All available data was considered, including new data presented during the 25th International Papillomavirus Conference (IPC) in May in Malmē¶, Sweden.
Mental Health

Phase Forward Introduces Empirica™ Study, Major New Release Of Clinical Trials Signal Detection Solution

Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced the availability of Empirica™ Study, formerly the Clinical Trials Signal Detection product (CTSD™). The Empirica Study solution helps clinical and safety teams improve their understanding of a product"s emerging safety profile during clinical development by facilitating the timely detection, review and analysis of safety issues in clinical trials data. Empirica Study joins the Empirica™ Signal and Empirica™ Trace products to round out Phase Forward"s Empirica Suite, which supports safety review and risk management across the product development lifecycle, from clinical trials through post-marketing. These products are managed by the company"s Lincoln Safety Group, one of the most experienced and respected teams in the safety industry. Empirica Study is an award-winning product that provides a dynamic visual data environment for reviewing safety data and detecting signals in trial data in CDISC Study Data Tabulation Model (SDTM) format. The new release streamlines study data updates for improved handling of in-stream data, and dramatically improves safety review and signal detection with new graphical displays and intuitive usability improvements for detailed drill-down and sophisticated graphical support. These capabilities complement the statistical algorithms and safety screening techniques which form the technical foundation for the product. This release includes the capability to apply its signal detection methods to a greater variety of more complex study designs, such as crossover studies. "With the increased availability of standardized data in CDISC format, study sponsors have even greater opportunities to delve into clinical data, surfacing potential safety issues earlier in the process," said Chan Russell, president of Phase Forward"s Lincoln Safety Group. "Using its statistical analysis algorithms, Empirica Study helps safety experts examine the most critical safety concerns and make informed decisions regarding the risk/benefit ratios of products in development." "Empirica Study includes both simple statistical tools that users with a clinical background will readily grasp and more sophisticated tools based on Bayesian statistics," said William DuMouchel, chief statistical officer at Phase Forward. "Our work with early adopters in industry and at the FDA suggest that as standardized clinical data becomes more widely available, these tools will allow reviewers to explore relationships between adverse events and the rich set of covariates available only in clinical trial data." Phase Forward will be showcasing its products including Empirica Study at DIA"s 45th Annual Meeting in San Diego at booth #729. The Empirica Suite of Products The Empirica Suite is Phase Forward"s complete solution set for pharmacovigilance and risk management. In addition to Empirica Study, the suite includes the Empirica Trace product for adverse event data management and reporting and its companion Empirica Gateway which offers full support for E2B submission of case reports to regulators, affiliates and partners and receipt of data via E2B standard files. The suite also includes Empirica Signal, a state-of-the-art data mining and signal management tool. It provides detection and quantification of safety signals through the use of advanced data mining techniques that can be applied to any spontaneous reporting database. Phase Forward"s safety products are used by regulatory authorities, biopharmas, medical device manufacturers and contract research organizations (CROs) of all sizes to implement proactive strategic pharmacovigilance programs. The product family name, Empirica, signifies the importance of empirical data in the decision-making process. Phase Forward


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009